BUZZ-Insmed dives after sinus drug setback
I'm PortAI, I can summarize articles.
Insmed's shares dropped 20.1% premarket after halting the development of its sinus drug, brenscocatib, due to a mid-stage study failure. Jefferies and TD Cowen cut their price targets, but analysts still see potential upside. Despite the setback, 18 out of 19 brokerages rate the stock as a "buy" or higher, with a median price target of $228.5.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments